LEXX - Lexaria Bioscience Corp. Stock Price, Fair Value and News

3.30USD+0.16 (+5.10%)Delayed as of 17 May 2024, 09:51 am ET

Market Summary

USD3.30+0.16

Delayedas of 17 May 2024, 09:51 am

5.10%

LEXX Stock Price

View Fullscreen

LEXX RSI Chart

LEXX Valuation

Market Cap

40.5M

Price/Earnings (Trailing)

-7.44

Price/Sales (Trailing)

99.97

EV/EBITDA

-14.12

Price/Free Cashflow

-7.77

LEXX Price/Sales (Trailing)

LEXX Profitability

Operating Margin

93.30%

EBT Margin

-582.87%

Return on Equity

-83.42%

Return on Assets

-85.64%

Free Cashflow Yield

-12.87%

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

404.7K

Rev. Growth (Yr)

624.09%

Rev. Growth (Qtr)

-4.15%

LEXX Earnings

Earnings (TTM)

-5.4M

Earnings Growth (Yr)

49.96%

Earnings Growth (Qtr)

44.92%

Breaking Down LEXX Revenue

52 Week Range

0.653.30

(Low)(High)

Last 7 days

-13.1%

Last 30 days

35.5%

Last 90 days

46.3%

Trailing 12 Months

323.8%

How does LEXX drawdown profile look like?

LEXX Financial Health

Current Ratio

66.29

LEXX Investor Care

Shares Dilution (1Y)

115.28%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	404.7K	0	0	0
2023	328.6K	322.1K	226.2K	279.8K
2022	489.1K	372.2K	255.4K	339.3K
2021	650.3K	817.9K	722.7K	605.9K
2020	406.7K	250.5K	252.6K	495.9K
2019	501.1K	628.6K	670.9K	626.6K
2018	183.5K	219.3K	289.1K	325.8K
2017	48.5K	68.6K	64.0K	113.9K
2016	67.7K	69.8K	86.5K	45.8K
2015	43.7K	44.8K	45.9K	62.6K
2014	863.1K	394.4K	159.1K	42.5K
2013	1.5M	1.6M	1.3M	1.1M
2012	1.1M	978.6K	1.1M	1.4M
2011	555.3K	748.2K	941.1K	1.1M
2010	0	0	0	362.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lexaria Bioscience Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2023	turkel catherine c.	bought	4,266	2.8446	1,500	-
Oct 14, 2022	downey gregory	bought	252	2.09	121	chief financial officer
Oct 14, 2022	downey gregory	acquired	252	2.09	121	chief financial officer
Oct 13, 2022	bunka christopher	bought	34,860	2.1	16,600	chief executive officer
Oct 13, 2022	bunka christopher	acquired	34,860	2.1	16,600	ceo
Oct 12, 2022	bunka christopher	bought	43,537	1.988	21,900	chief executive officer
Oct 12, 2022	bunka christopher	acquired	43,537	1.988	21,900	ceo
May 24, 2022	reese albert l jr	acquired	9,790	1.958	5,000	-
May 20, 2022	reese albert l jr	acquired	3,610	2.007	1,799	-
May 19, 2022	reese albert l jr	acquired	3,017	2.01	1,501	-

Which funds bought or sold LEXX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	new	-	142,663	142,663	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-46.36	20,606	57,557	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-5,958	-	-%
May 15, 2024	Royal Bank of Canada	added	1,748	26,000	26,000	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-53.49	2,547	9,808	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	sold off	-100	-98,688	-	-%
May 15, 2024	Invenomic Capital Management LP	reduced	-35.34	802,976	1,717,950	0.09%
May 15, 2024	ADAR1 Capital Management, LLC	added	1,537	94,620	96,652	0.02%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	860	860	-%
May 15, 2024	MORGAN STANLEY	new	-	84,775	84,775	-%

Are Funds Buying or Selling LEXX?

Are funds buying LEXX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LEXX

No. of Funds

Unveiling Lexaria Bioscience Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	boos wayne w	4985%	1,020,000	SC 13D/A
Feb 14, 2024	boos wayne w	7078%	480,000	SC 13D/A
Feb 14, 2024	invenomic capital management lp	7.12%	731,981	SC 13G/A
Sep 18, 2023	boos wayne w	6129%	450,000	SC 13D
Feb 10, 2023	invenomic capital management lp	7.95%	473,103	SC 13G/A
Feb 14, 2022	invenomic capital management lp	6.03%	359,113	SC 13G
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	2.6%	159,000	SC 13G/A
Feb 24, 2021	bunka christopher	9.5%	489,455	SC 13D/A

Recent SEC filings of Lexaria Bioscience Corp.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 02, 2024	D	D
Apr 30, 2024	8-K	Current Report

Peers (Alternatives to Lexaria Bioscience Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Lexaria Bioscience Corp. News

Latest updates

Lexaria Bioscience Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.1%	145	151	15.00	93.00	20.00	98.00	111	100	31.00	31.00	31.00	204	192	296	126	36.00	38.00	52.00	124	193	257
Gross Profit	-1.0%	145	146	-3.43	80.00	17.00	82.00	70.00	81.00	24.00	8.00	11.00	144	161	231	134	16.00	-20.56	2.00	110	57.00	13.00
Operating Expenses	-36.8%	813	1,286	1,107	2,464	1,341	1,777	818	2,499	1,473	2,012	1,313	2,711	1,266	944	916	1,426	1,041	979	1,226	1,245	1,166
S&GA Expenses	-20.2%	567	711	606	823	645	948	462	1,747	1,197	1,553	874	2,256	1,090	752	3,785	55.00	61.00	74.00	90.00	82.00	52.00
R&D Expenses	-57.2%	246	574	500	1,641	696	829	356	752	276	459	440	454	176	192	68.00	25.00	187	107	162	231	66.00
EBITDA Margin	27.9%	-5.47*	-7.59*	-9.40*	-6.45*	-6.33*	-6.40*	-8.49*	-5.82*	-4.42*	-3.56*	-2.99*	-2.64*	-3.32*	-	-	-	-	-	-	-	-
Interest Expenses	-Infinity%	-1*	-	-	-	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	5.00	-	-	-	13.00	-	-	3.00	3.00	10.00	2.00	-957*	-27.79	-	14.00
EBT Margin	28.2%	-5.83*	-8.12*	-10.04*	-6.74*	-6.61*	-6.70*	-8.89*	-6.10*	-4.64*	-3.75*	-3.14*	-2.78*	-3.49*	-	-	-	-	-	-	-	-
Net Income	44.9%	-649	-1,179	-1,239	-2,371	-1,298	-1,755	-1,467	-2,382	-1,425	-1,993	-1,178	-2,566	404	-696	-714	-1,390	-950	-907	-37.73	-16.13	-5.13
Net Income Margin	38.2%	-13.44*	-21.76*	-29.46*	-20.45*	-20.09*	-20.73*	-28.46*	-10.84*	-8.25*	-6.66*	-5.59*	-4.37*	-3.69*	-	-	-	-	-	-	-	-
Free Cashflow	47.6%	-619	-1,181	-1,621	-1,785	-1,241	-1,265	-1,176	-1,265	-1,277	-1,208	-1,112	-1,156	-911	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	75.1%	6,352	3,627	3,084	5,240	4,855	6,213	7,834	9,138	11,415	11,746	13,267	10,548	12,172	2,174	2,828	3,320	1,986	2,746	2,675	3,457	4,274
Current Assets	101.1%	5,417	2,694	2,151	4,235	4,004	5,359	6,978	8,291	10,572	10,901	12,443	9,686	10,946	1,308	1,926	2,528	1,180	1,911	1,819	2,608	3,641
Cash Equivalents	140.8%	4,705	1,954	1,352	3,164	3,272	4,533	5,813	7,051	8,359	9,682	10,918	8,109	9,347	525	1,294	2,034	740	1,333	1,285	1,996	1,996
Inventory	-	-	-	-	-	8.00	10.00	38.00	40.00	32.00	27.00	30.00	52.00	137	126	117	133	124	134	127	188	108
Net PPE	-3.1%	226	234	254	277	301	311	316	343	-	-	368	-	423	452	483	511	538	565	591	607	433
Liabilities	-19.6%	204	254	404	1,198	223	282	201	225	195	277	203	281	470	353	346	120	63.00	130	185	132	500
Current Liabilities	-34.4%	82.00	125	268	1,056	223	282	194	207	166	238	153	221	399	242	226	91.00	63.00	130	185	132	500
Shareholder's Equity	93.3%	6,521	3,373	3,044	4,395	4,632	5,932	7,632	8,913	11,220	11,469	13,064	10,266	11,703	1,821	2,482	3,201	1,923	2,615	2,491	3,325	3,773
Retained Earnings	-1.4%	-47,592	-46,942	-45,763	-44,524	-42,152	-40,854	-39,098	-37,631	-35,248	-33,822	-31,829	-	-28,094	-28,498	-27,802	-27,087	-25,725	-24,775	-23,868	-22,789	-21,618
Additional Paid-In Capital	6.8%	54,121	50,671	48,799	48,912	47,121	47,110	47,041	46,809	46,697	45,498	45,089	40,990	39,860	30,373	30,324	30,184	27,525	27,221	26,172	25,891	24,319
Shares Outstanding	20.1%	12,388	10,312	8,092	8,092	5,951	5,951	5,951	5,951	5,951	5,727	5,727	5,104	3,524	3,001	-	-	-	-	-	-	-
Minority Interest	-0.9%	-372	-369	-364	-354	-342	-329	-316	-270	-235	-212	-202	-77.51	-67.96	-57.04	-42.94	14.00	43.00	90.00	108	145	995
Float	-	-	-	-	-	16.20*	-	-	-	21,000	-	-	-	27,000	-	-	-	21,566	-	-	-	83,889

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	47.6%	-619	-1,181	-1,621	-1,785	-1,228	-1,245	-1,176	-1,259	-1,277	-1,166	-1,112	-1,156	-911	-809	-639	-670	-753	-555	-736	-1,101	-603
Share Based Compensation	-100.0%	-	54.00	10.00	81.00	11.00	69.00	233	111	-	409	-	344	17.00	49.00	-	683	294	162	119	443	-
Cashflow From Investing	-42.4%	-56.99	-40.03	-68.44	-33.65	-32.68	-34.84	-50.04	-37.96	-34.42	-58.21	-2*	-70.73	270	-5.77	-13.64	-7.49	-1*	-5.71	-33.09	-1,239	670
Cashflow From Financing	89.8%	3,453	1,819	-121	1,711	-	-	-11.20	-11.20	-11.20	-10.99	4,004	-10.99	9,435	-8.77	-89.15	1,916	120	707	59.00	1,243	381

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LEXX Income Statement

2024-02-29

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
Revenue	$ 145,000	$ 20,025	$ 296,278	$ 117,760
Cost of goods sold	0	2,958	4,822	18,753
Gross profit	145,000	17,067	291,456	99,007
Operating expenses
Research and development	245,779	696,178	820,270	1,525,667
General and administrative	567,226	644,514	1,278,333	1,592,384
Total operating expenses	813,005	1,340,692	2,098,603	3,118,051
Loss from operations	(668,005)	(1,323,625)	(1,807,147)	(3,019,044)
Other income (loss)
Interest income (expense)	(1)	14,990	7,318	18,731
Unrealized gain (loss) on marketable securities	15,273	(2,003)	(37,942)	(79,631)
Total other income (loss)	15,272	12,987	(30,624)	(60,900)
Net loss	(652,733)	(1,310,638)	(1,837,771)	(3,079,944)
Less: Net loss attributable to non-controlling interest	(3,194)	(12,507)	(8,909)	(25,869)
Net loss attributable to Lexaria shareholders	(649,539)	(1,298,131)	(1,828,862)	(3,054,075)
Other comprehensive loss
Foreign currency translation adjustment	(24,998)	0	(20,626)	0
Total comprehensive loss	$ (674,537)	$ (1,298,131)	$ (1,849,488)	$ (3,054,075)
Basic and diluted loss per share	$ (0.06)	$ (0.22)	$ (0.18)	$ (0.52)
Weighted average number of common shares outstanding
- Basic and diluted	10,765,143	5,950,998	9,970,489	5,950,998

LEXX Balance Sheet

2024-02-29

CONSOLIDATED BALANCE SHEETS - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Current
Cash	$ 4,705,399	$ 1,352,102
Marketable securities	87,699	125,642
Accounts receivable	357,090	126,686
Prepaid expenses and other current assets	266,796	546,783
Total Current Assets	5,416,984	2,151,213
Non-current assets, net
Long-term receivables	39,494	48,559
Right of use assets	149,997	167,446
Intellectual property, net	519,253	462,625
Property & equipment, net	226,315	254,143
Total Non-current Assets	935,059	932,773
TOTAL ASSETS	6,352,043	3,083,986
Current Liabilities
Accounts payable and accrued liabilities	55,318	239,941
Lease liability, current	26,399	27,794
Total Current Liabilities	81,717	267,735
Lease liabilities - non-current	122,486	136,173
TOTAL LIABILITIES	204,203	403,908
Share Capital
Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding: 12,387,673 and 8,091,650 at February 29, 2024 and August 31, 2023, respectively.	12,388	8,091
Additional paid-in capital	54,121,316	48,799,454
Accumulated Deficit	(47,592,289)	(45,763,427)
Accumulated other comprehensive income	(20,626)	0
Equity attributable to shareholders of Lexaria	6,520,789	3,044,118
Non-controlling interest	(372,949)	(364,040)
Total Stockholders' Equity	6,147,840	2,680,078
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,352,043	$ 3,083,986

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.

CEO	Mr. Christopher A. Bunka
WEBSITE	https://lexariabioscience.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Lexaria Bioscience Corp. Frequently Asked Questions

What is the ticker symbol for Lexaria Bioscience Corp.? What does LEXX stand for in stocks?

LEXX is the stock ticker symbol of Lexaria Bioscience Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexaria Bioscience Corp. (LEXX)?

As of Thu May 16 2024, market cap of Lexaria Bioscience Corp. is 40.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LEXX stock?

You can check LEXX's fair value in chart for subscribers.

What is the fair value of LEXX stock?

You can check LEXX's fair value in chart for subscribers. The fair value of Lexaria Bioscience Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lexaria Bioscience Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LEXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lexaria Bioscience Corp. a good stock to buy?

The fair value guage provides a quick view whether LEXX is over valued or under valued. Whether Lexaria Bioscience Corp. is cheap or expensive depends on the assumptions which impact Lexaria Bioscience Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LEXX.

What is Lexaria Bioscience Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, LEXX's PE ratio (Price to Earnings) is -7.44 and Price to Sales (PS) ratio is 99.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LEXX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lexaria Bioscience Corp.'s stock?

In the past 10 years, Lexaria Bioscience Corp. has provided 0.018 (multiply by 100 for percentage) rate of return.